AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
MindWalk Holdings Corp. (NASDAQ: HYFT) announced a binding commitment for a $30 million senior unsecured revolving credit facility from Sanabil (Cayman) at a fixed 7.00% annual interest rate with no financial…
Editor's note: This article has been republished from its original version. Certain sections have been supplemented with a summary, key facts and answers to common questions, each drawn from and verified against the original release. Article also has sponsored disclosure at bottom. The original article can be viewed here.
AUSTIN, Texas, Sept. 14, 2026 /PRNewswire/ -- USA News Group News Commentary - Artificial intelligence is moving from the edges of drug discovery toward its center, and the market built around it is expanding quickly. Grand View Research values the global AI in drug discovery market at approximately $2.9 billion in 2026 and projects it will reach roughly $13.8 billion by 2033, a compound annual growth rate (CAGR) of about 24.8%. That growth is running into a constraint no algorithm has solved. AI-driven biotech still has to be paid for, and how a company funds the build is becoming as closely watched as what it builds. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), Tempus AI, Inc. (NASDAQ: TEM), Palantir Technologies Inc. (NASDAQ: PLTR), Moderna, Inc. (NASDAQ: MRNA), and Schrödinger, Inc. (NASDAQ: SDGR).
Forecasts vary widely depending on how the category is drawn, but they point the same way. Global Market Insights sizes the market at about $4.0 billion in 2026 and projects approximately $43.9 billion by 2035, a CAGR of roughly 30.5%, citing generative AI, predictive analytics and multi-omics data integration as the drivers.
The capital behind those forecasts has been uneven. Law firm Gibson Dunn's 2026 life sciences outlook describes a bifurcated but improving equity market, built on catalyst-driven follow-on financings, alongside a continued expansion of non-dilutive and alternative financing. Goodwin has reported that royalty financings in biopharma totaled roughly $29.4 billion from 2020 through 2024, more than double the amount raised over the prior five years, as companies looked for capital without the dilution of an equity raise.
The terms attached to that money matter as much as the amount. In its Summer 2026 life sciences financing review, Covington & Burling noted that recent U.S. court decisions have led most synthetic royalty and drug development financings to require security over intellectual property and other product assets. For an AI-native company whose value sits in its data, models and patents, whether capital takes a lien on those assets is not a footnote.
Against that backdrop, one Nasdaq-listed Bio-Native AI company has announced a financing structured to avoid both dilution and asset security.
MindWalk Holdings Corp. (NASDAQ: HYFT) Secures $30 Million Unsecured Credit Facility at 7.00% With No Financial Covenants and No Dilution
- Binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to $30 million
- Fixed 7.00% annual interest, accruing only on amounts drawn, plus a one-time 1.00% opening fee
- No lien, pledge or security interest over any MindWalk asset, and no financial maintenance covenant
- No warrants, no conversion feature, and no restriction on MindWalk's equity programs
- 36-month term, extendable by 12 months by agreement at no fee; prepayable at par at any time
MindWalk Holdings Corp. announced that it has entered into a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to $30 million. The facility carries a fixed interest rate of 7.00% per annum, accruing only on amounts actually drawn. According to the Company, there is no unused line fee, no financial maintenance covenant, no warrants and no conversion feature, and MindWalk grants no security over any of its assets. Obligations rank pari passu with MindWalk's other unsecured debt. Further information is available through the Company's investor relations site.
"This facility funds our biologics programs and our commercial build without issuing a single share," said Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp. "We chose debt over equity here for a straightforward reason. We were not prepared to sell any part of this business at the current share price, and we did not have to. Sanabil took no warrants, no conversion feature, and no security over any asset we own, so the full benefit of executing our plan stays with the shareholders who own it today. Our commercial model is recurring and backloaded by design, and this gives us the balance sheet to carry across that curve on our own terms."
Under the key terms outlined by the Company, amounts repaid may be reborrowed, and interest plus the one-time opening fee are the only amounts payable, with no commitment fee, extension fee or prepayment penalty. Draws require three business days' notice, with a $250,000 minimum and up to $7.5 million per quarter, and unused quarterly capacity carries forward. Commitments can be reduced in $1 million steps at no cost, and MindWalk is never obliged to borrow. Reporting is satisfied by the Company's SEC filings. The terms also include no material-adverse-change condition to closing and no default triggered by a material adverse effect, with share price, market conditions, sector conditions and clinical or regulatory outcomes expressly excluded.
The lender side carries its own restrictions. Sanabil is barred from shorting or hedging MindWalk shares and from trading on material non-public information, and assignment of the facility is restricted, including to competitors and to any person who would become a 5% holder.
The Company ties the structure directly to how it earns revenue. MindWalk describes its commercial model as recurring and backloaded by design: ReefIQ™ engagements enrich the underlying biological representation as programs run on it, and LensAI™ engagements deepen as customers move from evaluation into production workflows, so contract economics accrue across the life of an engagement rather than at signature. The facility is intended to fund operations and program execution across that recognition curve without issuing equity. The Company notes that the facility takes no lien over MindWalk's patents, source code, model weights, training data or datasets. Proceeds are available for working capital and general corporate purposes.
That representation is the asset the structure is built to protect. MindWalk describes itself as a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require. At its core is HYFT® Technology, a proprietary, function-aware representation of biology that, refined over 20 years of curation, forms a biological representation of 660 million patterns and 25 billion relationships. It underpins ReefIQ, the biological context layer for life sciences, and LensAI, the reasoning and application layer for target discovery, candidate diligence, portfolio decision support and agentic AI workflows. In its fiscal 2026 results, released July 22, 2026 for the year ended April 30, 2026, the Company reported revenue up 46%.
The parties will negotiate a definitive credit agreement consistent with the term sheet, which MindWalk expects to file as a material contract exhibit with its next periodic report.
There are several risks associated with the Company's plans. The facility is a binding commitment under a term sheet, and a definitive credit agreement has not yet been negotiated or executed, so final terms may differ; the Company's own forward-looking statements identify the risk that the agreement is not executed, or not executed by the target closing date, and the risk that it does not satisfy the conditions to closing and to drawing. Amounts drawn must be serviced and repaid, and the Company identifies further risks including acceleration of outstanding amounts and termination of undrawn commitments on an event of default, and a prepayment event requiring repayment within 30 days if a change of control or a delisting of its common shares occurs. Revenue under MindWalk's commercial agreements is weighted to later periods of each engagement and may not be recognized on the timetable or in the amounts expected, contracted engagements may not be renewed or expanded, and additional capital may not be available on acceptable terms. Information about the lender is limited to the Company's own description. Investors should review MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ and EDGAR.
Read this and more news at: https://usanewsgroup.com
In other industry developments and happenings in the market this week include:
Investors should review MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ and EDGAR .
Tempus AI, Inc. (NASDAQ: TEM)
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, recently reported second-quarter 2026 revenue of $382.5 million, up 22% year over year, with its Data Licensing and Modeling (Insights) revenue up 36%. The company said it signed roughly $200 million in new Data and Applications licenses during the quarter, and raised its full-year 2026 revenue guidance to $1.595 billion to $1.605 billion.
Tempus has been busy on the capital side as well. During the first half it completed a $460 million offering of 0.0% convertible senior notes due 2032, and its cash flow statement shows it repaid its revolving credit facility and long-term debt over the same period. It ended June with $820.7 million in cash and marketable securities. On July 20, 2026, it agreed to acquire Personalis for $16.25 per share, approximately $1.5 billion in enterprise value, with closing expected in late Q4 2026 or early 2027.
"Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing," said Eric Lefkofsky, Founder and CEO of Tempus.
Palantir Technologies Inc. (NASDAQ: PLTR)
Palantir Technologies Inc. (Nasdaq: PLTR), whose software platforms are deployed across government and commercial enterprises, holds the same instrument MindWalk has just secured and has never needed to use it. As of June 30, 2026, Palantir reported no outstanding debt balances and $500 million of available and undrawn revolving commitments under its credit facility, alongside $2.03 billion in cash and cash equivalents and $7.38 billion in marketable securities.
The scale explains the posture. Palantir reported second-quarter 2026 revenue of $1.935 billion, up 93% year over year, with United States commercial revenue up 149% to $764 million, net income of $1.066 billion and diluted earnings per share of $0.41. First-half operating cash flow reached $2.12 billion. The company raised full-year 2026 revenue guidance to between $8.15 billion and $8.158 billion and adjusted free cash flow guidance to between $4.5 billion and $4.7 billion, and disclosed remaining performance obligations of $4.9 billion. It also entered a long-term cloud hosting commitment of at least $5.6 billion in minimum spend through February 2036, a reminder that an undrawn facility is a buffer rather than a substitute for the obligations a platform business takes on.
"Forget consensus," Chief Executive Officer Alex Karp told CNBC following the results. "To my knowledge, no businesses at our scale has even grown half this much."
Moderna, Inc. (NASDAQ: MRNA)
Moderna, Inc. (Nasdaq: MRNA), the mRNA platform company, is running the opposite play: drawing on a credit facility while cutting the cost base it has to service. The company has projected year-end 2026 cash and investments of $4.5 billion to $5.0 billion, a figure it states excludes any further drawdowns from the $0.9 billion remaining available under its credit facility. It ended the second quarter with $6.9 billion in cash and investments.
The cost discipline is the story underneath that. Moderna reduced cash costs by 10% year over year in the second quarter and lowered full-year 2026 cash cost guidance to approximately $4 billion, with GAAP operating expenses of approximately $4.7 billion excluding a non-recurring litigation settlement charge, each roughly $0.2 billion better than prior guidance. Research and development expenses fell $256 million, or 16%, across the first half. That follows approximately $2.2 billion of annual operating expense reductions delivered in 2025.
Second-quarter revenue of $145 million exceeded the top of the company's range against a net loss of $782 million, an improvement of 5% on the prior year, and the company paid $950 million in July in connection with a litigation settlement. Moderna reiterated a target of up to 10% revenue growth for 2026. For a company of that size, a partially drawn facility sitting alongside a shrinking cost base is a different use of the same instrument MindWalk has just put in place at a far earlier stage.
Schrödinger, Inc. (NASDAQ: SDGR)
Schrödinger, Inc. (NASDAQ: SDGR), whose physics-based computational platform is licensed by biotechnology, pharmaceutical and industrial companies and academic institutions, is putting outside capital to work on its own discoveries. On September 9, 2026, it announced a licensing and collaboration agreement with Tectora Therapeutics, an immunology and inflammation company it co-founded with New Enterprise Associates and RA Capital Management, which concurrently closed a $55 million Series A. Schrödinger contributed two early-stage programs, SDGR-4594 and SDGR-8139, in exchange for an equity stake in Tectora and eligibility for future milestones and royalties.
Karen Akinsanya, Ph.D., Schrödinger's President, Therapeutics R&D and Chief Strategy Officer, Partnerships, pointed to the company's record of building programs for licensing or launching companies with venture partners, including Nimbus, Morphic, Structure and Ajax, which she said "have collectively generated over $750 million in proceeds to Schrödinger."
Frequently Asked Questions
What are the key terms of MindWalk's $30 million credit facility?
The facility carries a fixed 7.00% annual interest rate accruing only on amounts drawn, a one-time 1.00% opening fee, no unused line fee, no financial maintenance covenant, no warrants, no conversion feature, and no security interest over any MindWalk assets; it has a 36-month term extendable by 12 months and is prepayable at par at any time.
How much revenue did MindWalk report in fiscal 2026?
MindWalk reported revenue up 46% in fiscal 2026 for the year ended April 30, 2026.
What is the size of the AI drug discovery market?
Grand View Research valued the global AI in drug discovery market at approximately $2.9 billion in 2026 and projects it will reach roughly $13.8 billion by 2033, with a compound annual growth rate of about 24.8%.
Why did MindWalk choose debt over equity for this facility?
CEO Jennifer Bath stated the company chose debt because it was not prepared to sell any part of the business at the current share price; Sanabil took no warrants, no conversion feature, and no security over assets, so the full benefit of executing the company's plan stays with current shareholders.
What are MindWalk's core technology assets and business model?
MindWalk describes itself as a Bio-Native AI company with HYFT Technology, a proprietary biological representation of 660 million patterns and 25 billion relationships that underpins ReefIQ and LensAI platforms; the commercial model is recurring and backloaded by design, with contract economics accruing across the life of an engagement.
Is the credit facility fully executed?
The facility is a binding commitment under a term sheet; a definitive credit agreement has not yet been negotiated or executed, so final terms may differ and there is no assurance the agreement will be executed by the target closing date.
Sources & Filings
Originally distributed via PR Newswire: AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Verify statements about the companies above against their own filings:
- SEC EDGAR filings — MindWalk Holdings (HYFT)
- SEC EDGAR filings — Palantir Technologies (PLTR)
- SEC EDGAR filings — Tempus AI (TEM)
- SEC EDGAR filings — Moderna (MRNA)
Related Coverage
Track the Signals Before the Crowd
The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Market Equities Limited, a company incorporated under the laws of Ireland ("MEL"), which wholly owns and operates USA News Group. MEL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). MEL also expects to receive further compensation as part of an ongoing digital media effort to increase visibility for the company. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved by MindWalk Holdings Corp. and CDMG. MEL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of MindWalk Holdings Corp. and may liquidate their shares, which could have a negative effect on the price of the stock. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may lose some or all of your investment. Market-size figures cited are third-party projections by independent research firms, are not MindWalk's addressable revenue, and may not be realized. The credit facility described in this publication is a binding commitment under a term sheet; a definitive credit agreement has not been executed, its final terms may differ from those described, and there is no assurance that it will be executed or that any amount will be drawn. Borrowing under the facility would create interest and repayment obligations, and the facility is subject to events of default, acceleration and mandatory prepayment provisions as described in the Company's disclosures. Information regarding the lender is limited to the Company's description and has not been independently verified by the publisher. Any MindWalk product candidates or therapeutic programs are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and descriptions of the Company's technology, commercial model and revenue timing reflect the Company's own statements. Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking information. Forward-looking statements are made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. Forward-looking statements are often, but not always, identified by the use of words such as "expects," "intends," "anticipates," "plans," "believes," "estimates," "projects," "may," "will," "could," "should," and similar expressions. These statements include, without limitation, statements regarding the execution and terms of a definitive credit agreement, the availability and use of proceeds under the facility, the Company's commercial model and the timing of revenue recognition, the pace of commercial adoption of the Company's platforms, the Company's capital resources and cash runway, and the growth of the AI in drug discovery market. Such statements are based on current expectations and assumptions and involve risks and uncertainties, including those set out in MindWalk Holdings Corp.'s Annual Report on Form 20-F and other filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this publication. The publisher undertakes no obligation to update any forward-looking statement, except as required by law.
